Cartesian funds Descartes-08 push to filing with cash lasting into 2028

Cartesian Therapeutics says it has enough money to reach its first possible regulatory submission. With its third-quarter 2026 results on 5 November, the company reported $124.7 million in cash, a total that includes a first $50 million tranche from K2HealthVentures. Management expects that to finance operations into 2028. The quarterly net loss was $11.5 million.

The runway matters because of what is scheduled inside it. Cartesian expects results from the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis patients with AChR antibodies in the first quarter of 2027. It then plans to file a Biologics License Application with the US Food and Drug Administration in mid-2027. Descartes-08 is an anti-BCMA CAR-T therapy. The filing plan depends on AURORA delivering a result that supports it.

The company also shared follow-up data on retreatment. Five MG patients who received a repeat course showed an average 6.6-point improvement on the MG-ADL scale at 12 months, and Cartesian did not report any fresh safety concerns in the group. The cohort is very small, so the figures offer an early indication rather than a firm picture of repeat dosing.

Further datasets are due in the first half of 2027: the TRITON study in myositis and the HELIOS study in paediatric patients. Cartesian has not set out in this update how those programmes would be developed commercially, so any expansion beyond adult MG remains an open question.